Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVIDENT: Individualized Treatment in Metastatic Colorectal Cancer
NCT05725200Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2038
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of alectinib, cetuximab, crizotinib, dasatinib, everolimus in metastatic colorectal cancer (mCRC), sponsored by Oslo University Hospital. Started Sep 2022; status: recruiting.
02
Drugs
alectinibcetuximabcrizotinibdasatinibeverolimus
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05725200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725200.